Holdings – Talk Bio

Avalyn Pharma Raises $100M to Advance Inhaled Lung Disease Drugs

1 month ago talkbio0Tagged AP01, AP02, aspects of adverse effects, Avalyn, Clinical Trials, drug safety, Holdings, inhaled lung disease, nintedanib, Pharma, pirfenidone, Pulmonary Fibrosis, Series D, SNCG gene, Suvretta Capital Management

Avalyn Pharma; $100 million Series D; inhaled lung disease medications; pulmonary fibrosis; AP01; AP02; pirfenidone; nintedanib; clinical trials; drug safety; side effects; Suvretta Capital Management; SR One; Novo Holdings

GlycoEra Raises $130M to Advance Protein Degraders Toward Clinic

3 months ago talkbio0Tagged Autoantibodies, Autoimmune Diseases, Clinical Trials, Funding, GE8820, GlycoEra, Holdings, Immunoglobulin IgG4, Precision Immunology, protein degraders

GlycoEra; protein degraders; $130 million funding; autoimmune diseases; GE8820; IgG4 autoantibodies; Novo Holdings; clinical trial; precision immunology

FDA Approves Ensartinib for First-Line Treatment of ALK-Positive NSCLC

9 months ago talkbio0Tagged (ALK)-positive, Approved, ensartinib, Holdings, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, United States Food and Drug Administration, Xcovery

Ensartinib, ALK-positive NSCLC, FDA approval, lung cancer treatment, Xcovery Holdings

Novo Holdings Spearheads $100M Series C Financing for SiteOne Therapeutics to Develop Non-Opioid Pain Therapies

9 months ago talkbio0Tagged Holdings, ion channel modulators, Non-Opioid Pain, Opioid Epidemic, pain chronic management, Peripheral Nervous System, Series C financing, SiteOne Therapeutics

Novo Holdings, SiteOne Therapeutics, Non-opioid pain treatments, Series C financing, Ion channel modulators, Peripheral nervous system (PNS) pain treatments, Chronic pain management, Opioid epidemic